CSF cyclic nucleotides and somatostatin in Parkinson's disease.
Concentrations of cyclic adenosine 3',5' monophosphate (cAMP) were significantly lower in parkinsonian patients than in controls, but concentrations of guanosine 3',5' monophosphate (cGMP) were not altered. Both cAMP and cGMP levels were lower in patients with more severe symptoms on the left side of the body. Somatostatin-like immunoreactivity (SLI) was similar in parkinsonian patients and controls. Both cAMP and SLI were significantly related to acetylcholinesterase activity.
Volicer
L
L
Beal
M F
MF
Direnfeld
L K
LK
Marquis
J K
JK
Albert
M L
ML
D000110:Acetylcholinesterase / Q000134:cerebrospinal fluid; D000368:Aged; D000242:Cyclic AMP / Q000134:cerebrospinal fluid*; D006152:Cyclic GMP / Q000134:cerebrospinal fluid*; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000201:enzymology; D011863:Radioimmunoassay; D013004:Somatostatin / Q000134:cerebrospinal fluid*
D013004:Somatostatin; D000242:Cyclic AMP; D000110:Acetylcholinesterase; D006152:Cyclic GMP; D006719:Homovanillic Acid